{'fraction_non_alphanumeric': 0.021996615905245348, 'fraction_numerical': 0.0, 'mean_word_length': 5.535911602209945, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
DNA-Edited Ligand Positioning on Red Blood Cells to Enable Optimized T Cell Activation for Adoptive Immunotherapy.

Artificial antigen presenting cells (APCs) with surface-anchored T cell activating ligands hold great potential in adoptive immunotherapy. However, it remains challenging to precisely control the ligand positioning on those platforms via conventional bioconjugation chemistry. Here, utilizing DNA-assisted bottom-up self-assembly, we are able to precisely control both lateral and vertical distribution of T cell activation ligands on red blood cells (RBCs). It is found that the clustered lateral positioning of peptide-major histocompatibility complex (pMHC) on RBCs with a short vertical distance to the cell membrane would be favorable for more effective T cell activation, likely owing to their better mimic of natural APCs. Such optimized RBC-based artificial APCs can stimulate T cell proliferation in vivo and effectively inhibit tumor growth via adoptive immunotherapy. DNA technology is thus a unique tool to precisely engineer the cell membrane interface and tune cell-cell interactions, promising for a wide range of applications including immunotherapy.